Q3-osavuosiraportti
Vain PDF
15 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
10 000
Myynti
Määrä
19 170
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 3 992 | - | - | ||
| 4 383 | - | - | ||
| 1 500 | - | - | ||
| 125 | - | - |
Ylin
4,46VWAP
Alin
4,24VaihtoMäärä
0,7 155 490
VWAP
Ylin
4,46Alin
4,24VaihtoMäärä
0,7 155 490
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenIt's absolutely clear that NHS is going fully digital now!💪- ·1 päivä sittenWould like to remind again that core operations with expansion to Sweden justify a higher share price than today's. The probability of success in the patient module is still not priced in, and represents the biggest upside. Now we can hope they manage to secure a contract. It could happen within just 3 weeks if the company's «guiding» is correct.
·1 päivä sittenTotally disagree regarding Sweden. The defense would have had a higher share price if they had actually secured more agreements since launch 9-10 months ago. The potential with 30 million in ARR there was hyped as hell. There are hopes that there will be improvements with the new sales resource then. So the battle is not lost. Yep, signing with AZ is not priced in yet. Should be at least 12 then, and gradually build up in the year after signing. If AZ is to buy up/make an offer, then the first year is also the best time for them to do it. The patient pathway is already validated and desired by NHS, but it is the larger rollout that will then truly prove how big a market share the whole setup gets. The better it looks (i.e., the larger the market share becomes), and the slower AZ is to eventually make an offer, the higher premium they have to pay. Regarding signing, it is much more likely that it will come after Christmas, but I doubt we will see anything before February actually. 3 weeks is far too early, given the timeline that has been. Things have taken and will take time.·1 päivä sittenThe basis is 50% market share in Sweden in 5 years. Might be too optimistic. AZ probably cannot acquire Induct due to regulatory reasons. I don't think they can or will. Evinova might acquire, but unsure. 
·2 päivää sittenGood momentum now!! 😂 hehe·1 päivä sittenSlowly, but surely upwards. Better that than those explosive rounds we had last time👍
·3 päivää sittenWeak on the sell side. People are holding onto them now.·2 päivää sitten · MuokattuThere will probably be more than enough time to acquire more shares before a deal comes. Loading up heavily at a good price will be more difficult then given the latest trend here. It's being held harder than in July. A deal in December would have been the best Christmas gift this year, but breaking news on the stock exchange is not what December is known for. I still envision that Q1 and delays (more details to be finalized with AZ) are most likely, but rather sooner than later. Christmas time is not a mega strategic time to release news either from a PR perspective. So if NHS wants to tell how good they are at modernizing, then February is a better choice. The mood from Christmas has lightened then. If we dip below 3.5 without any changes, it's prime buy time again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
Vain PDF
15 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIt's absolutely clear that NHS is going fully digital now!💪
- ·1 päivä sittenWould like to remind again that core operations with expansion to Sweden justify a higher share price than today's. The probability of success in the patient module is still not priced in, and represents the biggest upside. Now we can hope they manage to secure a contract. It could happen within just 3 weeks if the company's «guiding» is correct.·1 päivä sittenTotally disagree regarding Sweden. The defense would have had a higher share price if they had actually secured more agreements since launch 9-10 months ago. The potential with 30 million in ARR there was hyped as hell. There are hopes that there will be improvements with the new sales resource then. So the battle is not lost. Yep, signing with AZ is not priced in yet. Should be at least 12 then, and gradually build up in the year after signing. If AZ is to buy up/make an offer, then the first year is also the best time for them to do it. The patient pathway is already validated and desired by NHS, but it is the larger rollout that will then truly prove how big a market share the whole setup gets. The better it looks (i.e., the larger the market share becomes), and the slower AZ is to eventually make an offer, the higher premium they have to pay. Regarding signing, it is much more likely that it will come after Christmas, but I doubt we will see anything before February actually. 3 weeks is far too early, given the timeline that has been. Things have taken and will take time.·1 päivä sittenThe basis is 50% market share in Sweden in 5 years. Might be too optimistic. AZ probably cannot acquire Induct due to regulatory reasons. I don't think they can or will. Evinova might acquire, but unsure.
- ·2 päivää sittenGood momentum now!! 😂 hehe·1 päivä sittenSlowly, but surely upwards. Better that than those explosive rounds we had last time👍
- ·3 päivää sittenWeak on the sell side. People are holding onto them now.·2 päivää sitten · MuokattuThere will probably be more than enough time to acquire more shares before a deal comes. Loading up heavily at a good price will be more difficult then given the latest trend here. It's being held harder than in July. A deal in December would have been the best Christmas gift this year, but breaking news on the stock exchange is not what December is known for. I still envision that Q1 and delays (more details to be finalized with AZ) are most likely, but rather sooner than later. Christmas time is not a mega strategic time to release news either from a PR perspective. So if NHS wants to tell how good they are at modernizing, then February is a better choice. The mood from Christmas has lightened then. If we dip below 3.5 without any changes, it's prime buy time again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
10 000
Myynti
Määrä
19 170
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 3 992 | - | - | ||
| 4 383 | - | - | ||
| 1 500 | - | - | ||
| 125 | - | - |
Ylin
4,46VWAP
Alin
4,24VaihtoMäärä
0,7 155 490
VWAP
Ylin
4,46Alin
4,24VaihtoMäärä
0,7 155 490
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
Vain PDF
15 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 12.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 13.11. | |
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2024 Yhtiökokous | 12.6. | |
| 2025 Q1-osavuosiraportti | 10.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenIt's absolutely clear that NHS is going fully digital now!💪
- ·1 päivä sittenWould like to remind again that core operations with expansion to Sweden justify a higher share price than today's. The probability of success in the patient module is still not priced in, and represents the biggest upside. Now we can hope they manage to secure a contract. It could happen within just 3 weeks if the company's «guiding» is correct.·1 päivä sittenTotally disagree regarding Sweden. The defense would have had a higher share price if they had actually secured more agreements since launch 9-10 months ago. The potential with 30 million in ARR there was hyped as hell. There are hopes that there will be improvements with the new sales resource then. So the battle is not lost. Yep, signing with AZ is not priced in yet. Should be at least 12 then, and gradually build up in the year after signing. If AZ is to buy up/make an offer, then the first year is also the best time for them to do it. The patient pathway is already validated and desired by NHS, but it is the larger rollout that will then truly prove how big a market share the whole setup gets. The better it looks (i.e., the larger the market share becomes), and the slower AZ is to eventually make an offer, the higher premium they have to pay. Regarding signing, it is much more likely that it will come after Christmas, but I doubt we will see anything before February actually. 3 weeks is far too early, given the timeline that has been. Things have taken and will take time.·1 päivä sittenThe basis is 50% market share in Sweden in 5 years. Might be too optimistic. AZ probably cannot acquire Induct due to regulatory reasons. I don't think they can or will. Evinova might acquire, but unsure.
- ·2 päivää sittenGood momentum now!! 😂 hehe·1 päivä sittenSlowly, but surely upwards. Better that than those explosive rounds we had last time👍
- ·3 päivää sittenWeak on the sell side. People are holding onto them now.·2 päivää sitten · MuokattuThere will probably be more than enough time to acquire more shares before a deal comes. Loading up heavily at a good price will be more difficult then given the latest trend here. It's being held harder than in July. A deal in December would have been the best Christmas gift this year, but breaking news on the stock exchange is not what December is known for. I still envision that Q1 and delays (more details to be finalized with AZ) are most likely, but rather sooner than later. Christmas time is not a mega strategic time to release news either from a PR perspective. So if NHS wants to tell how good they are at modernizing, then February is a better choice. The mood from Christmas has lightened then. If we dip below 3.5 without any changes, it's prime buy time again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
10 000
Myynti
Määrä
19 170
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 3 992 | - | - | ||
| 4 383 | - | - | ||
| 1 500 | - | - | ||
| 125 | - | - |
Ylin
4,46VWAP
Alin
4,24VaihtoMäärä
0,7 155 490
VWAP
Ylin
4,46Alin
4,24VaihtoMäärä
0,7 155 490
Välittäjätilasto
Dataa ei löytynyt